Rigel Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Company Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
Rigel Pharma (RIGL) Misses Q4 EPS by 1c, Revenues Beat
February 28, 2019 4:28 PM ESTRigel Pharma (NASDAQ: RIGL) reported Q4 EPS of $0.02, $0.01 worse than the analyst estimate of $0.03. Revenue for the quarter came in at $37.9 million versus the consensus estimate of $36.35 million.
Fourth quarter 2018 total revenues were $37.9 million; including $30.6 million in collaboration revenues and $7.3 million in net product sales of TAVALISSE® (fostamatinib disodium hexahydrate) for the treatment of thrombocytopenia in... More